Physician profile
Veronica Santee
NPI 1447283759
$2,825.78
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2021: $100 · 2022: $866 · 2023: $796 · 2024: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,444.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $610.95 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $381.85 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $337.04 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $274.99 | 2019-2023 | |
| Abbvie INC. | $216.05 | 2021-2024 | Ubrelvy, Vraylar, Creon |
| Boston Scientific Corporation | $194.70 | 2022-2023 | Watchman Access System, Rezum Generator |
| Daiichi Sankyo INC. | $115.68 | 2022 | |
| Merck Sharp & Dohme LLC | $81.42 | 2019-2024 | Varivax, M-M-R II, Capvaxive |
| Exact Sciences Corporation | $74.37 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $58.02 | 2024 | |
| Shield Therapeutics INC | $55.67 | 2023-2024 | Accrufer |
| Astrazeneca Pharmaceuticals Lp | $44.47 | 2022-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $44.21 | 2019 | |
| Dexcom, INC. | $44.10 | 2023-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.16 | 2022-2023 | Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $36.72 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.43 | 2023 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $33.86 | 2019-2024 | Camzyos |
| Edwards Lifesciences Corporation | $29.84 | 2022 | |
| Abbott Laboratories | $23.86 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $23.39 | 2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $20.79 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.56 | 2024 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $16.54 | 2022 | |
| Mylan Specialty L.P. | $14.11 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Santee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.